The PI3K signalling pathway is frequently deregulated in human solid tumours including breast cancers through Akt1 or PIK3CA (catalytic subunit of PI3K) mutations, HER2 overexpression and PTEN loss or mutation [24,25,29-34]. Here, ERBB2 is linked to breast carcinoma.